Cigna Group (NYSE:CI) Issues Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Cigna Group (NYSE:CI) issued its quarterly earnings results on Thursday. The health services provider reported $8.08 EPS for the quarter, topping analysts’ consensus estimates of $7.88 by $0.20, FiscalAI reports. The business had revenue of $72.50 billion during the quarter, compared to the consensus estimate of $69.53 billion. Cigna Group had a net margin of 2.29% and a return on equity of 18.80%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.64 earnings per share. Cigna Group updated its FY 2026 guidance to 30.250- EPS.

Here are the key takeaways from Cigna Group’s conference call:

• The Cigna Group reported full-year adjusted revenue of $275 billion (11% growth) and adjusted EPS of $29.84 for 2025, and guided to at least $30.25 adjusted EPS for 2026 while returning over $5 billion to shareholders in 2025.
• Management announced a global FTC settlement resolving PBM matters (including the insulin case) that it says will deliver roughly $7 billion in out-of-pocket relief over 10 years and provides regulatory clarity that aligns with Cigna’s new rebate‑free PBM model, which Cigna plans to adopt for its fully insured book in 2027 and for at least 50% of Evernorth by end‑2028.
• Ascent GPO capabilities will be moved from Switzerland to the U.S., which management said could raise the company’s effective tax rate by up to about 1% over time if not mitigated.
• Evernorth’s specialty and care services remain a key growth driver (14% revenue growth; specialty scripts +13% in 2025), now representing roughly 35% of the company and supported by biosimilar uptake and strategic investments like Shields Health Solutions.
• The quarter included after‑tax special items of $483 million ($1.82 per share), and management plans back‑half weighted investments to build the rebate‑free PBM infrastructure that could pressure early‑2026 earnings and cash flow (2026 operating cash flow guide of ~$9 billion vs $9.6 billion in 2025).

Cigna Group Stock Up 3.9%

CI traded up $10.64 during trading hours on Thursday, reaching $282.35. 2,079,294 shares of the stock traded hands, compared to its average volume of 1,673,186. Cigna Group has a fifty-two week low of $239.51 and a fifty-two week high of $350.00. The company has a market cap of $75.42 billion, a price-to-earnings ratio of 12.49, a PEG ratio of 0.98 and a beta of 0.27. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.76 and a quick ratio of 0.76. The firm’s fifty day simple moving average is $274.37 and its two-hundred day simple moving average is $283.96.

Institutional Trading of Cigna Group

Hedge funds and other institutional investors have recently modified their holdings of the business. Man Group plc boosted its holdings in Cigna Group by 215.5% in the second quarter. Man Group plc now owns 532,183 shares of the health services provider’s stock valued at $175,929,000 after purchasing an additional 363,510 shares during the last quarter. Corient Private Wealth LLC raised its position in shares of Cigna Group by 257.4% in the 2nd quarter. Corient Private Wealth LLC now owns 389,637 shares of the health services provider’s stock valued at $127,811,000 after purchasing an additional 280,616 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Cigna Group by 17.2% during the 3rd quarter. Invesco Ltd. now owns 1,900,502 shares of the health services provider’s stock valued at $547,820,000 after buying an additional 279,564 shares during the last quarter. Amundi increased its stake in shares of Cigna Group by 14.3% in the third quarter. Amundi now owns 1,570,065 shares of the health services provider’s stock worth $475,212,000 after buying an additional 196,613 shares during the last quarter. Finally, Raymond James Financial Inc. increased its stake in shares of Cigna Group by 16.2% in the third quarter. Raymond James Financial Inc. now owns 1,322,897 shares of the health services provider’s stock worth $381,325,000 after buying an additional 184,158 shares during the last quarter. 86.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CI shares. Truist Financial upped their target price on Cigna Group from $310.00 to $320.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Cantor Fitzgerald cut their price objective on shares of Cigna Group from $365.00 to $325.00 in a report on Friday, October 31st. Raymond James Financial restated a “strong-buy” rating on shares of Cigna Group in a report on Monday, November 3rd. Robert W. Baird decreased their price target on shares of Cigna Group from $372.00 to $315.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Cigna Group from $415.00 to $301.00 and set a “buy” rating for the company in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $323.84.

Key Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Q4 results beat on both EPS and revenue — Cigna reported $8.08 EPS and $72.5B revenue, ahead of estimates, showing solid year-over-year margin and revenue growth. Cigna Q4 results / transcript
• Positive Sentiment: Management raised the quarterly dividend and reiterated adjusted income from operations guidance (at least $30.25 per share for 2026), supporting yield and signaling confidence in cash flow. PR Newswire: 2025 results and 2026 outlook
• Positive Sentiment: Evernorth (PBM) growth helped lift revenue, an important driver of top-line momentum going forward. WSJ: Evernorth lifts revenue
• Positive Sentiment: Some analysts remain constructive — Guggenheim issued a Buy rating, which can support investor sentiment. Analyst: Guggenheim buy rating
• Neutral Sentiment: The FTC settlement with Express Scripts removes a legal overhang but commits the company to drug-pricing changes; the net impact on long-term PBM economics is uncertain and will depend on implementation. Reuters: Cigna settles FTC insulin case
• Neutral Sentiment: Market commentary and previews highlight Cigna as a quality healthcare holding but note valuation and near-term growth caution from some analysts. Seeking Alpha: Cigna thesis
• Negative Sentiment: Cigna’s FY2026 EPS guidance (~$30.25) came in slightly below Wall Street’s consensus (~$30.35), signaling near-term margin pressure from medical costs — a headwind for the stock despite the quarter’s strength. Reuters: 2026 forecast misses expectations
• Negative Sentiment: Some coverage frames the FTC settlement as forcing concessions by Express Scripts that could pressure PBM margins and pricing dynamics for employers and pharmacies. GlobeNewsWire: FTC squeezes concessions

About Cigna Group

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.